IXICO PLC's (LON:IXI) Lammert Albert talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study.
Albert describes this as a 'strong suit' having started very early and now carrying out a Phase III study into a treatment for the disease.
IXICO added the contract will not have a significant performance for the coming year but will add to the company's order book for the year after.
